IBM's ability to implement enterprise AI relies on the watsonx platform, with the conversion of To-B AI orders in 2026 being a key KPI; its PE of around 20x is within a reasonable range.
Tempus AI focuses on medical AI data analysis, with revenue growth exceeding 40% but still unprofitable; its valuation needs to be measured by the PS ratio, and a PS of around 15x indicates high market expectations.
C3 AI recently missed both earnings and revenue estimates and lowered its guidance, with its stock price falling over 20%; it is currently an underperformer, awaiting signals of a fundamental rebound next quarter.
The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
